These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21714601)

  • 1. Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus.
    Angiolillo DJ; Roffi M; Fernandez-Ortiz A
    Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):697-710. PubMed ID: 21714601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
    Tan GM; Lam YY; Yan BP
    Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multidisciplinary management of patients with acute coronary syndrome and diabetes mellitus: from antithrombotic therapy to treatment of hyperglycemia].
    Rossini R; Cimino A; De Servi S; Grieco N; Lettieri C; Mafrici A; Musumeci G; Perseghin G; Sponzilli C; Trevisan R; Visconti LO; ; ;
    G Ital Cardiol (Rome); 2014 Jun; 15(6):378-92. PubMed ID: 25072424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current concepts on coronary revascularization in diabetic patients.
    Roffi M; Angiolillo DJ; Kappetein AP
    Eur Heart J; 2011 Nov; 32(22):2748-57. PubMed ID: 21893486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes.
    Ferreiro JL; Cequier AR; Angiolillo DJ
    Trends Cardiovasc Med; 2010 Oct; 20(7):211-7. PubMed ID: 22293020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current perspectives on coronary revascularization in the diabetic patient.
    Roffi M; Brandle M; Robbins MA; Mukherjee D
    Indian Heart J; 2007; 59(2):124-36. PubMed ID: 19122245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet therapy in acute coronary syndromes.
    Aragam KG; Bhatt DL
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):24-42. PubMed ID: 20924098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and acute coronary syndrome.
    Keller PF; Carballo D; Roffi M
    Minerva Med; 2010 Apr; 101(2):81-104. PubMed ID: 20467408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of P2Y
    Zhang Y; Zhang S; Ding Z
    Adv Exp Med Biol; 2017; 906():307-324. PubMed ID: 27628007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute coronary syndrome in patients with diabetes mellitus: perspectives of an interventional cardiologist.
    Sanon S; Patel R; Eshelbrenner C; Sanon VP; Alhaddad M; Oliveros R; Pham SV; Chilton R
    Am J Cardiol; 2012 Nov; 110(9 Suppl):13B-23B. PubMed ID: 23062562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction.
    Manoukian SV
    Am J Cardiol; 2009 Sep; 104(5 Suppl):9C-15C. PubMed ID: 19695355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Wiviott SD
    Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes and antiplatelet therapy in acute coronary syndrome.
    Ferreiro JL; Angiolillo DJ
    Circulation; 2011 Feb; 123(7):798-813. PubMed ID: 21343595
    [No Abstract]   [Full Text] [Related]  

  • 20. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.